

ELAN BAPINEUZUMAB STUDIES

Elan Protocol 301: HUM18451

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN 115727) in Subjects with Mild to Moderate Alzheimer's Disease who are Apolipoprotein Eε4 Non-Carriers. This is a multicenter, randomized, double-blind and placebo-controlled study. In this protocol subjects nor the investigators will know if they are receiving the actual medication.

Elan 302: HUM 18565

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN 115727) in Subjects with Mild to Moderate Alzheimer's Disease who are Apolipoprotein Eε4 Carriers. This is a multicenter, randomized, double-blind and placebo-controlled study. In this protocol subjects nor the investigators will know if they are receiving the actual medication.

Study Purpose

The purpose of these research studies will assess whether Bapineuzumab is safe, well tolerated and effective for use in subjects with Alzheimer's disease. Bapineuzumab is an investigational drug and has not been approved for the treatment of Alzheimer's disease. Bapineuzumab is an antibody (a type of protein usually produced by white blood cells to destroy other substances in the body). In Alzheimer's disease a protein called amyloid gathers in the brain and is thought to cause symptoms like memory loss and confusion. It is being tested to determine if bapineuzumab will attach to the amyloid protein in your brain and help your body to remove it.

You will receive study drug, or placebo, on 6 separate occasions, once every 13 weeks, over a period of 65 weeks. You will be asked to return to the site for additional safety visits for 13 more weeks. Approximately 18-22 months in total.

For more information contact: Joanne L. Lord LPN, BA, CCRC 734-647-7760